Xizang Haisco Pharmaceutical vs Zhejiang Huahai Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Xizang Haisco Pharmaceutical Group Co Ltd (002653.CS)

Q3 20268 Jul – 8 Sep 2026

▲3▼1

Haisco Soars on Profit Surge and New Licensing Deals

Profit Surge and Strong Financials Haisco's first-half net profit jumped 513–575% on innovative drug sales and licensing upfronts, with revenue of 3.1 billion yuan and net profit of 851 million yuan, boosting investor confidence.
This massive earnings growth was a primary driver of the stock's positive performance.
Major Licensing Deals Validate Platform New deals including a $75.89 million upfront Sentivera agreement potentially worth $1.5 billion and AbbVie's HSK51155 partnership validated Haisco's drug discovery platform and future revenue potential.
These deals provided significant external validation and upfront cash, fueling optimism.
Pipeline Progress and Dividend Confidence HSK60002 approval and partner AirNexis' positive Phase 2b COPD trial advanced the pipeline, while a planned 600 million yuan dividend and subsidiary funding signaled cash confidence.
Pipeline milestones and capital returns reinforced growth prospects and financial health.
Tax Compliance Issue Weighs Slightly A tax bureau flagged a subsidiary for receiving 1.26 million yuan in fake VAT invoices, creating modest compliance and penalty risk that slightly weighed on shares.
This was the main negative factor, though its impact was limited.

August 20268 Jul – 8 Sep 2026

▲3▼1

Haisco Soars on Profit Surge and New Licensing Deals

Profit Surge and Strong Financials Haisco's first-half net profit jumped 513–575% on innovative drug sales and licensing upfronts, with revenue of 3.1 billion yuan and net profit of 851 million yuan, boosting investor confidence.
This massive earnings growth was a primary driver of the stock's positive performance.
Major Licensing Deals Validate Platform New deals including a $75.89 million upfront Sentivera agreement potentially worth $1.5 billion and AbbVie's HSK51155 partnership validated Haisco's drug discovery platform and future revenue potential.
These deals provided significant external validation and upfront cash, fueling optimism.
Pipeline Progress and Dividend Confidence HSK60002 approval and partner AirNexis' positive Phase 2b COPD trial advanced the pipeline, while a planned 600 million yuan dividend and subsidiary funding signaled cash confidence.
Pipeline milestones and capital returns reinforced growth prospects and financial health.
Tax Compliance Issue Weighs Slightly A tax bureau flagged a subsidiary for receiving 1.26 million yuan in fake VAT invoices, creating modest compliance and penalty risk that slightly weighed on shares.
This was the main negative factor, though its impact was limited.

Latest2 Aug – 8 Sep 2026

▲3▼1

Haisco's profit, pipeline wins and dividend offset tax-invoice hit

Tax bureau flags false invoices at Haisco subsidiary A tax bureau named a Haisco holding subsidiary among five drugmakers that received fake VAT invoices worth 1.26 million yuan from a now-deregistered vendor. The amount is small, but it raises compliance and possible penalty risk, a modest drag on the shares.
It is the only clearly negative regulatory event in the period and a real counterweight to the good news.
Interim profit of 851 million yuan on 3.1 billion revenue Haisco's first-half 2026 report showed revenue of 3.096 billion yuan and net profit of 851 million yuan, with strong cash flow and a 17.68% return on equity. Solid earnings and a healthy balance sheet support the stock's value.
The interim results are the core fundamental update that tells readers how the business is actually performing.
New drug approvals and partner trial success lift pipeline Haisco's HSK60002 tablet won Chinese clinical trial approval for inflammatory disease, and partner AirNexis said AN01 met its main goal in a China Phase 2b COPD study run by Haisco. Both validate the pipeline and raise hopes for future revenue.
These are the period's main technology catalysts that can drive long-term growth expectations.
Dividend and subsidiary funding show cash confidence Haisco plans to pay 5.26 yuan per 10 shares, about 600 million yuan, and will lend up to 261 million yuan to its new biotech subsidiary for ADC and CAR-T research. Returning cash while funding growth signals confidence in its finances.
The payout and internal funding show management's confidence and support shareholder returns, a positive capital signal.

8 Jul – 26 Aug 2026

▲4

Haisco's profit surge and new licensing deals drive gains

First-half profit forecast up over 500% Haisco expects first-half net profit to rise 513% to 575% year-on-year, driven by rapid innovative drug sales and upfront payments from out-licensing deals. This signals strong earnings momentum and boosts investor confidence in the stock.
This is the core earnings catalyst that directly explains the stock's positive momentum.
New pain drug HSK51155 gets clinical trial approval Haisco's self-developed oral pain drug HSK51155 received clinical trial approval in China. It is part of a global partnership with AbbVie worth over $700 million, validating Haisco's research capabilities and adding a potential future revenue stream.
This pipeline advancement supports long-term growth prospects and reinforces the value of Haisco's licensing strategy.
New autoimmune licensing deal with Sentivera Haisco licensed a preclinical autoimmune asset to US-based Sentivera for $75.89 million upfront (cash plus equity), up to $1.46 billion in milestones, and royalties. This brings immediate cash and validates Haisco's drug discovery platform.
This is a fresh, material deal that directly adds near-term cash and potential long-term value.
Sentivera launch highlights China biotech out-licensing trend Sentivera, backed by Metsera investors, licensed Haisco's immunology asset, with total deal value potentially exceeding $1.5 billion. This NewCo model is gaining traction, boosting Haisco's reputation and future deal-making potential.
It underscores the growing demand for Chinese biotech assets and Haisco's ability to secure favorable terms.

Zhejiang Huahai Pharmaceutical Co Ltd (600521.CG)

Q3 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

August 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

Latest24 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.